Supplemental material
Journal of Market Access & Health Policy
Volume 5, 2017 - Issue 1
Open access
3,031
Views
16
CrossRef citations to date
0
Altmetric
Article
The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change
K. E. YoungPricing, Reimbursement, and Market Access, Creativ-Ceutical, Paris, FranceCorrespondence[email protected]
, I. SoussiPricing, Reimbursement, and Market Access, Creativ-Ceutical, Tunis, Tunisia
& M. ToumiDepartment of Public Health, Aix-Marseille Université, Marseille, France
http://orcid.org/0000-0001-7939-7204
Article: 1369817
|
Received 17 May 2017, Accepted 03 Aug 2017, Published online: 03 Sep 2017
Related Research Data
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
Source:
Springer Science and Business Media LLC
Non-profit drug research and development: the case study of Genethon
Source:
Informa UK Limited
Pricing and reimbursement of orphan drugs: the need for more transparency
Source:
Springer Science and Business Media LLC
Congenital diaphragmatic hernia.
Source:
Springer Science and Business Media LLC
European Union Pharmaceutical Markets: A Case for Differential Pricing?
Source:
Informa UK Limited
Access to orphan drugs in Europe: current and future issues
Source:
Informa UK Limited
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Source:
Public Library of Science (PLoS)
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.